Your browser is no longer supported. Please, upgrade your browser.
Settings
ONCY Oncolytics Biotech Inc. daily Stock Chart
ONCY [NASD]
Oncolytics Biotech Inc.
Index- P/E- EPS (ttm)-0.73 Insider Own1.80% Shs Outstand24.65M Perf Week-14.73%
Market Cap27.12M Forward P/E- EPS next Y-0.54 Insider Trans0.00% Shs Float24.65M Perf Month3.77%
Income-14.10M PEG- EPS next Q-0.11 Inst Own2.50% Short Float4.87% Perf Quarter54.97%
Sales- P/S- EPS this Y5.10% Inst Trans284.56% Short Ratio2.08 Perf Half Y-35.29%
Book/sh0.12 P/B9.17 EPS next Y- ROA-117.90% Target Price- Perf Year-45.81%
Cash/sh0.38 P/C2.92 EPS next 5Y- ROE-387.60% 52W Range0.35 - 2.50 Perf YTD-39.23%
Dividend- P/FCF- EPS past 5Y16.90% ROI- 52W High-55.40% Beta2.09
Dividend %- Quick Ratio3.80 Sales past 5Y- Gross Margin- 52W Low217.66% ATR0.14
Employees30 Current Ratio3.80 Sales Q/Q- Oper. Margin- RSI (14)56.53 Volatility10.12% 11.88%
OptionableNo Debt/Eq0.19 EPS Q/Q22.70% Profit Margin- Rel Volume0.94 Prev Close1.10
ShortableYes LT Debt/Eq0.08 EarningsNov 12 AMC Payout- Avg Volume578.34K Price1.12
Recom- SMA202.80% SMA5030.25% SMA200-16.31% Volume398,113 Change1.36%
Dec-09-19 07:00AM  Oncolytics Biotech(R) Announces Positive Multiple Myeloma Data Presented at the 61st Annual Meeting & Exposition of the American Society of Hematology ACCESSWIRE
Dec-06-19 07:00AM  Oncolytics Biotech(R) Regains Compliance with Nasdaq Minimum Bid Price Requirement ACCESSWIRE
Dec-03-19 07:00AM  Oncolytics Biotech(R) Presents Clinical Data at the Fifth Annual Oncolytic Virotherapy Conference Highlighting Definitive Evidence of Systemic Delivery and Replication of Pelareorep in Tumor Tissue ACCESSWIRE
Nov-25-19 10:03AM  Companies Like Oncolytics Biotech (TSE:ONC) Can Be Considered Quite Risky Simply Wall St. +5.77%
Nov-12-19 04:00PM  Oncolytics Biotech(R) Reports 2019 Third Quarter Financial Results and Operational Highlights ACCESSWIRE
07:00AM  Oncolytics Biotech(R) Announces Exercise of Warrants ACCESSWIRE
Nov-08-19 07:00AM  Oncolytics Biotech(R) Announces AWARE-1 Data Presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer ACCESSWIRE
Nov-07-19 07:00AM  Oncolytics Biotech(R) Announces Abstract Published for the 61st Annual Meeting & Exposition of the American Society of Hematology ACCESSWIRE -9.84%
Nov-06-19 07:00AM  Oncolytics Biotech(R) Announces Publication of Positive REO 024 Study Results for Pelareorep in Combination with Keytruda(R) in Patients with Advanced Pancreatic Adenocarcinoma ACCESSWIRE +7.02%
Nov-05-19 07:00AM  Oncolytics Biotech(R) to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights ACCESSWIRE -14.29%
Oct-31-19 07:00AM  Oncolytics Biotech(R) Provides Update on Partner Adlai Nortyes Clinical Progress ACCESSWIRE +7.76%
Oct-22-19 07:00AM  Oncolytics Biotech(R) and PrECOG Announce Collaboration for BRACELET-1 (PrE0113) Study in Metastatic Breast Cancer ACCESSWIRE
Oct-17-19 07:00AM  Oncolytics Biotech(R) Appoints Experienced Financial and Strategic Leader Leonard Kruimer to Board of Directors ACCESSWIRE
Oct-15-19 07:00AM  Oncolytics Biotech(R) Presents Clinical Data Highlighting the Effectiveness of Intravenous Delivery to and Replication of Pelareorep in Tumors ACCESSWIRE +10.56%
Oct-01-19 07:00AM  Oncolytics Biotech(R) Announces Abstract to be Presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer ACCESSWIRE -9.15%
Sep-30-19 07:00AM  Oncolytics Biotech CEO, Matt Coffey, Honored with Scientific Achievement and Innovation Award by BioAlberta ACCESSWIRE
Sep-25-19 07:00AM  Oncolytics Biotech(R) Announces Upcoming Presentation at the 12th Annual International Oncolytics Virus Conference ACCESSWIRE
Sep-23-19 07:00AM  Oncolytics Biotech(R) Announces Upcoming Conference Participation ACCESSWIRE -6.29%
Sep-20-19 07:00PM  Oncolytics Biotech(R) Receives Nasdaq Notification Letter ACCESSWIRE
Sep-17-19 07:00AM  Oncolytics Biotech(R) to Present at the Ladenburg Thalmann Healthcare Conference ACCESSWIRE
Sep-05-19 06:00PM  Oncolytics Biotech(R) to Present at the H.C. Wainwright 21st Annual Global Investment Conference ACCESSWIRE
Sep-04-19 07:00AM  Oncolytics Biotech(R) to Host Corporate Update Call to Discuss Recent Highlights and Expanded Catalysts and Milestones ACCESSWIRE +6.60%
Aug-16-19 08:55AM  Oncolytics Biotech(R) Announces Closing of Its Public Offering of Common Shares and Warrants ACCESSWIRE +16.24%
Aug-15-19 07:45AM  The Daily Biotech Pulse: Mallinkckrodt's Terlipressin, Deciphera Offering, Sellas Reboots On Earnings Benzinga -6.55%
Aug-14-19 02:30PM  CORRECTION: Oncolytics Biotech(R) Announces Pricing of Its USD $3.7M - CDN $4.9M Public Offering of Common Share and Warrants ACCESSWIRE -35.56%
08:45AM  Oncolytics Biotech(R) Announces Pricing of Its Public Offering of Common Share and Warrants ACCESSWIRE
Aug-13-19 04:15PM  Oncolytics Biotech(R) Announces Public Offering of Common Shares and Warrants ACCESSWIRE -7.21%
04:10PM  Oncolytics Biotech(R) Reports 2019 Second Quarter Financial Results and Operational Highlights ACCESSWIRE
Jul-23-19 07:00AM  Oncolytics Biotech(R) Announces Preliminary AWARE-1 Trial Data Demonstrating Viral Replication and Promotion of Inflammation Following Systemic Administration of Pelareorep When Combined with Tecentriq(R) ACCESSWIRE
Jun-05-19 07:00AM  Oncolytics Biotech (R) to Host Conference Call to Discuss Co-Development Agreement with Pfizer and Merck KGaA ACCESSWIRE
07:00AM  Oncolytics Biotech (R) Announces Study to Investigate Combination of Pelareorep and Avelumab in Metastatic Breast Cancer in Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer ACCESSWIRE
May-29-19 07:00AM  Oncolytics Biotech(R) to Present at the 9th Annual LD Micro Invitational Investor Conference ACCESSWIRE
May-16-19 07:00AM  Oncolytics Biotech (R) Publishes Abstract Highlighting Additional Biomarker Analyses at the 2019 American Society of Clinical Oncology Annual Meeting ACCESSWIRE
May-03-19 07:00AM  Oncolytics Biotech(R) Announces Voting Results from the Annual General Meeting of Shareholders ACCESSWIRE
07:00AM  Oncolytics Biotech (R) Reports 2019 First Quarter Financial Results and Operational Highlights ACCESSWIRE
Apr-25-19 07:00AM  Oncolytics Biotech(R) Announces Details of 2019 Annual General Meeting of Shareholders ACCESSWIRE
Apr-23-19 07:00AM  Oncolytics Biotech(R) to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference ACCESSWIRE
Apr-08-19 07:00AM  Oncolytics Biotech(R) Announces First Patient Treated in Company's AWARE-1 Window of Opportunity Study of Pelareorep in Breast Cancer ACCESSWIRE
Apr-04-19 07:00AM  Oncolytics Biotech(R) to Host Key Opinion Leader Meeting on the Emerging Role of Biomarkers and Oncolytic Viruses in the Treatment of Cancer ACCESSWIRE
Apr-03-19 07:00AM  Oncolytics Biotech(R) to Present at the 18th Annual Needham Healthcare Conference ACCESSWIRE
Apr-02-19 07:00AM  Oncolytics Biotech (R) Presents Positive Clinical Biomarker Data at the American Association for Cancer Research Annual Meeting 2019 ACCESSWIRE
Mar-28-19 07:00AM  Oncolytics Biotech (R) Announces a Publication Highlighting Synergistic Effect of Pelareorep with a Proteasome Inhibitor in Preclinical Models of Multiple Myeloma ACCESSWIRE
Mar-08-19 07:00AM  Oncolytics Biotech (R) Announces 2018 Year-End Results and Operational Highlights ACCESSWIRE +6.99%
Mar-01-19 07:00AM  Oncolytics Biotech(R) to Host Conference Call to Discuss Year End Financial Results and Operational Highlights ACCESSWIRE
Feb-28-19 04:31PM  Penny Stocks to Buy Using Technical Analysis for March 2019 Investopedia -10.35%
Feb-27-19 04:55PM  Oncolytics Biotech(R) Presents Biomarker Data in Second-line Pancreatic Cancer at AACR ACCESSWIRE +8.10%
Feb-11-19 07:00AM  Oncolytics Biotech(R) Announces Spanish Regulatory Approval of AWARE-1 Window of Opportunity Study in Breast Cancer ACCESSWIRE
Feb-04-19 07:00AM  Oncolytics Biotech(R) to Present at the 21st Annual BIO CEO & Investor Conference ACCESSWIRE +5.19%
Dec-12-18 07:00AM  Oncolytics Biotech® Announces First Patient Treated in Study Combining Pelareorep, Carfilzomib and the Checkpoint Inhibitor Opdivo® in Multiple Myeloma GlobeNewswire +10.58%
Dec-03-18 07:00AM  Oncolytics Biotech® Announces Increased PD-L1 Expression When Combining Pelareorep with a Proteasome Inhibitor in Poster Presentation at the 60th American Society of Hematology Annual Meeting & Exposition GlobeNewswire
Nov-29-18 07:00AM  Oncolytics Biotech® Announces Appointment of Rita Laeufle, M.D., as Chief Medical Officer GlobeNewswire
Nov-27-18 07:32AM  The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial Benzinga +6.44%
Nov-26-18 08:00AM  Oncolytics Biotech® Announces First Patient Treated in Phase 2 Study Combining Pelareorep and Keytruda® in Advanced Pancreatic Cancer GlobeNewswire
Nov-13-18 07:00AM  Oncolytics Biotech® Announces Attendance of Upcoming Conferences GlobeNewswire -8.71%
Nov-12-18 07:00AM  Oncolytics Biotech® Reports 2018 Third Quarter Financial Results and Provides Corporate Update GlobeNewswire
Nov-09-18 07:00AM  Oncolytics Biotech® Announces Presentation at the Society for Immunotherapy of Cancer 2018 Annual Meeting Showcasing Upregulation of PD-L1 Expression with Reovirus Infection GlobeNewswire
Nov-05-18 07:00AM  Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Corporate Highlights GlobeNewswire
Nov-01-18 07:00AM  Oncolytics Biotech® Announces Abstract for ASH Annual Meeting & Exposition Demonstrating Pelareorep Increases PD-L1 Expression When Combined with a Proteasome Inhibitor GlobeNewswire -5.86%
Oct-24-18 08:25PM  Oncolytics Biotech® Establishes New At-The-Market Facility GlobeNewswire
Oct-22-18 07:00AM  Oncolytics Biotech® Announces Positive Clinical Trial Results for Pelareorep in Patients with KRAS Mutant Metastatic Colorectal Cancer for Presentation at ESMO 2018 GlobeNewswire
Oct-11-18 07:00AM  Oncolytics Biotech® Announces Publication of Positive Clinical Results for Pelareorep in Abstract for ESMO 2018 Congress GlobeNewswire
Oct-02-18 07:00AM  Oncolytics Biotech® Announces a Publication Demonstrating That Intravenously Delivered Oncolytic Viruses Effectively Target Tumors Even in the Presence of Neutralizing Antibodies GlobeNewswire
Sep-28-18 08:36AM  Oncolytics Biotech® Enters into Common Stock Purchase Agreement for up to US$26 Million with Lincoln Park Capital, LLC GlobeNewswire
Sep-26-18 07:00AM  Oncolytics Biotech® to Present at the Ladenburg Thalmann 2018 Healthcare Conference GlobeNewswire
Sep-19-18 04:00PM  Oncolytics Biotech® Provides Corporate and Clinical Update GlobeNewswire
Sep-17-18 07:00AM  Oncolytics Biotech® Announces Investigator Sponsored Multiple Myeloma Study Combining REOLYSIN® and Nivolumab (Opdivo®) with Standard of Care GlobeNewswire -10.11%
Sep-10-18 07:00AM  Oncolytics Biotech® Collaborates with SOLTI to Conduct a Window of Opportunity Study in Breast Cancer with Pelareorep GlobeNewswire -5.64%
Sep-06-18 07:00AM  Oncolytics Biotech® Announces a Master Clinical Supply Agreement of an Anti-PD-L1 Checkpoint Inhibitor for use in the Companys Clinical Program GlobeNewswire +8.09%
Aug-03-18 07:00AM  Oncolytics Biotech® Reports 2018 Second Quarter Results GlobeNewswire -8.54%
Jul-31-18 07:00AM  Oncolytics Biotech® to Present at the Canaccord Genuity 38th Annual Growth Conference GlobeNewswire
Jun-06-18 10:25AM  ONCY: It Has Been a Busy Week or Two Zacks Small Cap Research
Jun-05-18 12:49PM  Oncolytics Biotech® Closes USD $8.9 Million Public Offering of Common Shares GlobeNewswire +11.52%
Jun-04-18 09:00AM  Oncolytics Biotech® Announces Poster Presentation Demonstrating the Ability of REOLYSIN® to Promote and Predict Response to Checkpoint Inhibitors at ASCO 2018 Annual Meeting GlobeNewswire
Jun-01-18 09:13AM  Oncolytics Biotech® Prices USD $8,000,000 Million Public Offering of Common Shares GlobeNewswire
07:40AM  Oncolytics Biotech® Announces Listing on Nasdaq Capital Market GlobeNewswire
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer. It has collaboration with PrECOG LLC. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.